Ozone Therapy for Women With Endometriosis

ConditionsEndometriosis Ozone Therapy Thermography

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexFemale

Age25-45

SponsorUniversidade Federal do Paraná

About this trial

To evaluate the action of ozone therapy as an adjuvant treatment in patients with endometriosis. Secondary Objective: To evaluate the efficacy of ozone therapy for pelvic analgesia in women with endometriosis; To compare the imaging diagnostic techniques of transvaginal ultrasound with infrared thermography in the pre-treatment (before), fourth, seventh and post-treatment (10th session) periods; To evaluate the application of the consolidated questionnaire (EHP-30) in the changes in the quality of life of the participants immediately after the intervention.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Women with a clinical diagnosis of endometriosis (ultrasonography / transvaginal exam)

25-45 years old

Disqualifiers

Pregnancy

G6PD positive

Addicted

HIV and hepatitis positive

Trial design

Design model

Single group

Treatments tested in this trial

Ozone therapy
Other intervention
The study also aims to analyze the efficacy of ozone therapy in participants affected by endometriosis, enriching the knowledge base in the field of women's health/gynecology. The expected results will contribute to improving current therapeutic approaches, informing clinical decisions and encouraging future research. Understanding the technique and its clinical applicability will help health professionals to offer personalized and effective treatments. In addition, the insights obtained can direct new investigations, such as the optimization of protocols or the exploration of innovative therapeutic combinations for even more satisfactory results. Based on the literature review and the biochemical properties of both techniques (ozone therapy and clinical approach), it may be possible that one of the approaches demonstrates a statistically superior advantage over the other. In addition, the research aims to investigate whether the quality of life of these participants will improve and i

Treatment groups

40 Participants

are divided into 1 treatment group

Group A: Ozone therapy on endometriosisExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

EHP-30 - Endometriosis Health Profile Questionnaire

The EHP-30 (Endometriosis Health Profile-30) is a disease-specific, patient-reported outcome measure designed to assess the health-related quality of life (HRQoL) in individuals with endometriosis on various aspects, including physical, emotional, and social well-being.

Time frame

EHP-30 will be applied at pre (baseline), through study completion, an average of 2 months.

Secondary outcomes

Thermographic images

Thermography, a non-invasive imaging technique that detects infrared radiation to map skin surface temperature, will be applied as a tool to assess the physiological response to ozone therapy in endometriosis. Ozone therapy, known for its anti-inflammatory and analgesic properties, may influence local blood flow and immune activity. Thermographic imaging allows visualization of these changes by capturing temperature variations in the abdominal or pelvic regions before (baseline), during (4 and 7th session) and after treatment (10th session). In endometriosis, affected areas often exhibit thermal asymmetry or increased heat due to inflammation. Post-ozone therapy, thermography can reveal reductions in localized hyperthermia, suggesting decreased inflammation and improved circulation. This method provides a visual, quantifiable means to monitor treatment response over time, offering a complementary assessment tool alongside symptom tracking.

Time frame

Infra-red images will be captured at pre (baseline), through study completion, an average of 2 months.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Universidade Federal do Paraná

Lead sponsor

Philozon Geradores de Ozonio LTDA

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: